Comments
Torrent Pharmaceuticals Limited announced standalone net profit for the quarter ended December 2020 at ₹278 crore as against ₹220 crore in the corresponding quarter a year ago, indicating a rise of 26 per cent. Company’s standalone revenues from operations for the quarter stood at ₹1,616 crore as against ₹1,471 crore in the same period last year.
On consolidated basis, net profit for the quarter stood at ₹297 crore as against ₹251 crore in the corresponding quarter a year ago. Consolidated revenues from operations were ₹1,995 crore for the quarter as against ₹1,966 crore in the same period last year. Company’s operating EBITDA increased by 12 per cent during the quarter at ₹607 crore.
India growth factors
The Board of Directors of the company, after its meeting held on Monday, announced interim dividend of ₹20 or 400 per cent for each equity shares of ₹5 each. The company’s India business during the quarter October-December grew by 7 per cent to ₹930 crore. The growth was aided by market recovery, continued momentum in chronic brands and strong recovery in sub-chronic brands, the company statement said.
In the US market, revenues during the quarter fell 24 per cent at ₹292 crore. The sales in Brazil fell 8 per cent on-year to ₹173 crore. However, revenues from Germany market rose by 21 per cent to ₹265 crore. Company’s shares ended 0.21 per cent up at ₹2,757.95 on NSE Monday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.